ME Therapeutics(AXSM)

Focus: ME Therapeutics is a publicly traded biotechnology company focused on immunology drugs targeting novel myeloid cell populations in oncology. Founded in 2023 and headquartered in New York, the company operates at an early clinical stage with a diversified pipeline.

Oncology

Profile data last refreshed 21h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Total Funding

$1B

Open Jobs

About ME Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow ME Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

4/9 — Basic

Company HealthStrong

Pipeline

Mid-stage

2 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Revenue

$271M

Pipeline & Clinical Trials

The Myelin Disorders Biorepository Project

Leukodystrophy

N/A

Mindfulness and Meditation-Based Relapse Prevention Program

Substance Use Disorders

N/A

Clinical Trials (1)

Help build intelligence for ME Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Public company with $315M cash position (FY 2025) provides stability for a 2023-founded biotech to execute multi-year development timelines
Focused immunology/oncology platform targeting myeloid cells represents a defined scientific thesis with potential for competitive advantage in a crowded IO space
Revenue inflection to $271M (FY 2025) from $50M (FY 2024) demonstrates commercial traction early in company lifecycle

Watch Out For

Only 1 active job opening and minimal hiring activity (1 Research role) signals limited near-term growth in headcount and career advancement velocity
Pipeline lacks clear clinical depth: 16 programs span disparate indications (oncology, dermatology, CNS, metabolic) with only 2 Phase 3 assets (Nailner, Rituximab), suggesting unfocused strategy or high attrition

Generated by Claude from ME Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

NCT07417579Mindfulness and Meditation-Based Relapse Prevention for Substance Use Disorders

N/A

Revascularization

Coronary Syndrome, Acute, Non-ST Elevation, High Risk Patients

N/A

Clinical Trials (1)

NCT06279663Management Tactics for Patients High Risk With Acute Coronary Syndrome Without ST Segment Elevation and Multivessel Coronary Artery Disease

N/A

Autoimmunity in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)

Myalgic Encephalomyelitis

N/A

Clinical Trials (1)

NCT03254823Autoimmunity in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)

N/A

Feasibility study of music-based mobile app

Dementia

N/A

Clinical Trials (1)

NCT06140342A Music-Based Mobile App for People Living With Alzheimer's Disease and Related Dementias (ADRD)